Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Allogene Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Allogene Therapeutics, Inc.’s stock price such as:

• Allogene Therapeutics, Inc.’s current stock price and volume
• Why Allogene Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ALLO from analysts
• ALLO’s stock price momentum as measured by its relative strength

About Allogene Therapeutics, Inc. (ALLO)

Before we jump into Allogene Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Want to learn more about Allogene Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Allogene Therapeutics, Inc..

Allogene Therapeutics, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 11:31 AM, CST, Allogene Therapeutics, Inc.’s stock price was $2.295.

Allogene Therapeutics, Inc. is up 1.1% from its previous closing price of $2.270.

During the last market session, Allogene Therapeutics, Inc.’s stock traded between $2.265 and $2.360. Currently, there are approximately 226.03 million shares outstanding for Allogene Therapeutics, Inc..

Allogene Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Allogene Therapeutics, Inc. Stock Price History

Allogene Therapeutics, Inc.’s (ALLO) price is currently up 7.75% so far this month.

During the month of May, Allogene Therapeutics, Inc.’s stock price has reached a high of $2.360 and a low of $2.080.

Over the last year, Allogene Therapeutics, Inc. has hit prices as high as $4.460 and as low as $0.862. Year to date, Allogene Therapeutics, Inc.’s stock is up 67.52%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Allogene Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded Allogene Therapeutics, Inc.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Allogene Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Allogene Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Allogene Therapeutics, Inc. (ALLO) by visiting AAII Stock Evaluator.

Relative Price Strength of Allogene Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Allogene Therapeutics, Inc. has a weighted four-quarter relative price strength of 15.86%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Allogene Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Allogene Therapeutics, Inc. Stock Price: Bottom Line

As of May 8, 2026, Allogene Therapeutics, Inc.’s stock price is $2.295, which is up 1.1% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Allogene Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.